G207 engineered herpes simplex virus: Phase I

MDG published in Gene Therapy that G207 was well tolerated in a

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE